Osarstad 80 Stella tablets treat hypertension (3 blisters x 10 tablets)

Valsartan does not inhibit the enzyme transferring angiotensin (also known as Kininase II) has the effect of converting angiotensin I into angiotensin II and degenerative bradykinin. Because there is no effect on the enzyme transferring angiotensin and does not enhance bradykinin or P substrate, Angiotensin II antagonists are not sure to be related to cough.

Pharmacokinetics

absorption

Valsartan is quickly absorbed after drinking with birth about 23%. The peak concentration of Valsartan in plasma is 2-4 hours after a dose.

Distribution

About 94 - 97% of the drug associated with plasma proteins.

Metabolism

Valsartan is negligible.

Elimination

The drug is excreted mainly in the form of unchanged. The sale time is about 5 - 9 hours. After drinking, about 83% of the drug is eliminated in feces and 13% in urine.

Caution when used

do not recommend simultaneous use with potassium supplements, potassium diuretics, potassium -containing salt substitutes or other drugs that can increase potassium levels (such as heparin). It is necessary to monitor potassium concentration appropriately.

In patients with sodium deficiency and/or severe loss of epidemic as users of high dosage diuretics, hypotension can occur in rare cases after starting treatment with Valsartan. Sodium and/or water compensation when starting with valsartan, such as reducing diuretics.

In patients with narrowed kidney stenosis on both sides or on the one side of the kidney artery, the safety use of Valsartan has not been established. However, drugs that affect the Renin - Angiotensin system may increase blood urea and serum creatinine in patients with kidney stenosis on the one hand, thus recommending renal function monitoring when the patient is treated with Valsartan.

Patients with primary Aldosterone should not be treated with Valsartan due to the Renin - Angiotensin system that is not activated in these patients.

Particularly cautious when prescribing patients with aortic valve stenosis or mitral valve stenosis, or congested myocardial hypertrophy.

Be cautious when starting treatment in patients after myocardial infarction/heart failure. Evaluation of patients after myocardial infarction/heart failure should include kidney function assessment. Using Valsartan in patients after myocardial infarction/heart failure often leads to somewhat reduced blood pressure, but the stop treatment due to hypotension is often not needed as long as the dose is in accordance with the instructions.

History of angioedema: Evala includes laryngeal swelling and barbar, causing obstruction of the airway, swelling of the face, lips, throat and/or tongue that has been reported in patients treated with Valsartan. Some patients who had previously had angels with drugs include ACE inhibitors. Stop using Valsartan right in angioedema patients, should not be reused.

Dual Renin - Angiotensin - Aldosterone (RAAS): Hypotension, fainting, stroke, hyperkalemia and kidney function changes (acute renal failure) have been reported in sensitive patients, especially if combined drugs affect this system.

Conditions are different from the irritation of the Renin - Angiotensin system: In patients with renal function depending on the activity of the Renin - Angiotensin system (such as patients with severe congestive heart failure), ACE inhibitors are associated with diuretic and/or Urea blood progression and in rare cases of acute renal failure and/or death. Because Valsartan is an Angiotensin II antagonistic drug, Valsartan can not be ruled out for kidney function impairment.

osarstad 80 contains lactose. This drug should not be used for patients with rare genetic problems galactose intolerance, total lactase enzyme deficiency or poor absorption of glucose - galactose.

The ability to drive and operate machinery

There is no data on the effects of Valsartan on the ability to drive and operate machinery. When driving or operating machinery, it should be noted occasionally dizziness or fatigue may occur during treatment with any hypertension.

Pregnancy

Medicines directly acting on the Renin - Angiotensin system that can cause damage and death for the fetus and infants when used for pregnant women. If you find pregnancy, you should stop using Valsartan as soon as possible.

The period of breastfeeding

is not sure whether Valsartan will be excreted through breast milk, but Valsartan is excreted through breastfeeding mice. Due to the ability to cause unwanted reactions in breastfeeding, deciding to stop breastfeeding or stop taking the drug after considering the importance of the drug on the mother.

Drug interaction

No recommendations to use simultaneously

Lithi: Increased lithe recovery lithium concentration and toxicity increased have been reported during use simultaneously ACE inhibitors. Due to the lack of experience in simultaneous use of Valsartan and Lithi, this combination is not recommended. If this combination is proven to be necessary, carefully monitoring lithium concentration.

Potassium diuretics, potassium supplements, salt -containing substances containing potassium and other substances can increase potassium levels: If a drug affects potassium concentration is considered to be in combination with Valsartan, so surveillance of plasma potassium concentration.

Be cautious when using simultaneously

Non -steroid anti -inflammatory drugs (NSAIDs), including selective inhibitors of COX - 2, acetylsalicylic acid> 3 g/day and non -selective NSAIDs: When Angiotensin antagonists are simultaneously used with NSAIDs, lowering blood pressure can decrease, increase the risk of bad kidney function and increase serum potassium. Therefore, it is recommended to monitor kidney function when starting treatment, as well as enough water for patients.

Transport substances: In vitro data shows Valsartan is the substrate of the shipping substances that absorb drugs into the OATP1B1/OATP1B3 liver and the drug transportation out of the liver MRP2. The clinical involvement of this finding is not known. Simultaneous use of drugs that inhibit drugs that absorb drugs into the liver (such as rifampin, cyclosporin) or drug transportation into the liver (such as ritonavir) can increase the levels of valsartan in the body. Should be cautious when starting or ending treatment simultaneously with these drugs.

Children: Hypertension in children and adolescents often encounter kidney abnormalities, recommend careful use of Valsartan and Valsartan and Renin - Angiotensin - Aldosterone inhibitors because they can increase serum potassium concentration. Kidney function and serum potassium level should be closely monitored.